Brendan Smith

Brendan Smith

Former Chief Financial OfficeratCRISPR Therapeutics AG· In proxies 2021–2023

Pay in FY2023-97% from the year before · CRISPR Therapeutics AG stock +54.0% the same year

Brendan Smith was paid $114.8K in FY2023 (Dec), down 97%. CRISPR Therapeutics AG stock rose 54.0% that year.

Pay$100 in the stock at the end of FY20 → $41
Pay is from the Summary Compensation Table of each CRISPR Therapeutics AG proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. CRISPR Therapeutics AGPublic company · 5 yr
    • Former Chief Financial Officer2021 – Present · 5 yrStock in role -68%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?